Podcasts about Epidemiology

Listen to JCO's Art of Oncology article, "A Fight Bigger Than Myeloma” by Dr. Adeel Khan, an Assistant Professor of Medicine and Public Health at UT Southwestern. The article is followed by an interview with Dr. Adeel Khan and host Dr. Mikkael Sekeres. Dr. Khan shares the story of a patient whose multiple myeloma diagnosis and treatment serves as a reminder of the civil liberties progress we've made and that we have more to go. TRANSCRIPT Narrator: A Fighter Bigger Than Myeloma, by Adeel M. Khan, MD, MPH, MS  I met her during the early part of my clinical training in hematology/oncology. She was in her late 70s, dressed in a rust-colored cardigan and a headwrap with patterns that reminded me of Ghanaian kente cloth. Her eyes were sharp, her tone polite but direct. You could tell from the moment she spoke that she had lived a life where she had to advocate—for herself, for her family, for her place in rooms that were not always welcoming.  Her chart said “multiple myeloma, R-ISS II,” but it did not say that she had first come to an emergency room at least a year earlier complaining of back pain and fatigue and had been told it was probably arthritis or old age. It did not mention that she had seen three different doctors before someone ordered the laboratory tests that finally began to work up her anemia and increasingly compromised kidney function. It would take another trio of doctors to eventually order a magnetic resonance imaging whose ghostly lytic lesions led down the path to a bone marrow biopsy and her cancer diagnosis. When I brought this up gently during one of our early appointments, she looked at me and said, “They don't hear pain the same when it comes from someone like me.” As a Black woman from the Deep South, she had grown up learning how to navigate a health care system that did not always believe her. She told me stories about being dismissed, misdiagnosed, and interrupted. She was born into an era of structural violence where she would be ignored at best and mistreated at worst. She carried the weight of those moments, but she also carried strength, and clarity, and the kind of dignity that made people sit up straighter in their leather chairs when she entered the room. She was one of the most quietly revolutionary people I have ever known, having grown up during a time of civil rights activism. She had even taken part in bending Dr King's long arc of the moral universe toward justice and could share story upon story from her glory days. Her myeloma treatments were not easy. Chemotherapy rarely is. She shared that there were days when her body was tired of fighting, when her bones ached, her blood counts dropped, and her neuropathic pain throbbed. In the back of my mind, I thought how tragic it was that her delayed diagnosis added unnecessary complications and whether she too thought of that. She was fully mindful of the issues people with her skin color faced in our American healthcare system and society as a whole and revealed how that motivated her to carry forward. “If I don't take up space here,” she told me once, “then someone else like me won't either.” Over the course of our visits, I came to understand that she did not see her myeloma as the hardest fight of her life. Not by a long shot. Her primary struggle was centered on life in Birmingham in the 1950s where separate but equal was still the law of the land; her mother cleaned houses, her father worked odd jobs, and her own prospects were uncertain. She admired the writings of Richard Wright and Jean Toomer and was not shy in sharing her passions. One day, during a particularly tough visit—her disease had progressed and we were down to limited options—I found myself meandering. We went through the usual workup and discussions: laboratory test results, symptoms, and treatment options. I offered the prospect of clinical trials, but she shook her head gently and said, “I've done my time in experiments—I can't give myself to a system that gave my people so little.” I paused. It was the first hint of what would become a larger conversation—not just about medicine, but about history. She was well aware of the atrocities of the Tuskegee syphilis trials in her home state, the Kligman experiments on incarcerated Black men, and the forced sterilization of women of color. As dependent upon medicine as she was in her old age, it carried a bloody stain of dehumanizing racism that soured her against it. Outwardly, I had little in common with her. As a young South Asian man growing up in times more conscious of racial injustice, I was far removed from these historical crimes. Although I learned of them during my education, I did not internalize their impact on the patients in front of me in clinic. But through her I came to comprehend just how scarring and enduring these events can be and how they can rob someone of trust. And the truth is the health care system had not treated her well. She had personal stories of doctors who did not believe her pain, nurses who assumed she was uneducated,  and being passed over for better options, better care, and better answers. “But I kept showing up,” she said. “Because that's what we do. We show up even when we're not wanted.” Her stories to me were revelations. In her younger years, she had helped organize teachers at her school when they tried to fire a fellow Black teacher who seemingly spoke too loud in a meeting. She had lived through redlining, through the crack epidemic, through watching young Black men vanish into prisons, and still she rose every day and worked as a public school teacher for decades. She worked for a system that largely did not work for her. I came to admire that about her—that in simply living day-to-day life with plain dignity and acute awareness of society's issues, she promoted change by living it. “You want to talk about cancer?” she once said, half laughing. “Try walking into a bank in 1972 with a good credit score and a Black face. That's a disease this country still hasn't cured.” Curiously, she did not say these things with bitterness. Not even anger, really. Just clarity. Like someone who had long ago made peace with the truth, even if it was sharp. In clinic, she challenged my every assumption—about treatment tolerance, about compliance, about who is difficult, and who is “advocating.” And she taught me to look differently at the ways bias lingers in medicine. Not just in data or policies, but in subtle moments: the tone we use when explaining options, the hesitations in our tests and referrals, and the assumptions we may not even realize we are making. And she did not just expect good care—she demanded it. She told me early on, “Don't you treat me like I'm anything other than your mother.” That landed. And in seeing patients before me now, I remind myself to wonder who they were in their past lives, what baggage burdens them, and how it all shapes their perspectives. So from my view, she fought multiple myeloma with everything she had, but from hers, she fought something bigger: an entire system shaped by inequality. And ultimately, she made me better to realize that, not just as a doctor, but as a human being. In my years since knowing her, completing my training, and beginning my practice, I reflect on her grace. I think not just about her life, but what it means to practice medicine in a world that often forgets what patients carry with them into the clinic—generations of weight, of injustice, of strength. Mikkael Sekeres: Welcome back to JCO's Cancer Stories, The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. I am so happy that today we are joined by Adeel Khan, who's Assistant Professor of Medicine and Public Health at UT Southwestern in Dallas to talk about his Journal of Clinical Oncology article, “A Fight Bigger than Myeloma.” Our guest's disclosures will be linked in the transcript. Adeel, thank you so much for contributing to JCO and for joining us to discuss your article. Adeel Khan: Thank you so much for having me. It's a pleasure to be here. Mikkael Sekeres: Adeel, I don't want to be disingenuous to our readers by acting as if we've just met. You and I have known each other for a decade since you were still in your training. I wonder if for our listeners you can tell us a little bit about yourself, where are you from and and walk us through your career so far. Adeel Khan: More than happy to. So, I grew up mostly in Oklahoma, but I've sort of lived around in the Northeast and here in the Southwest where I am currently. I did college at the University of Oklahoma. I did medical school at the University of Michigan. I did residency with good fortune at the Cleveland Clinic where I happened to get to know you and have continued to know you since. I did my fellowship then in hematology oncology at Beth Israel Deaconess in the Harvard system and along the way of all that I did a Masters of Public Health at Harvard and a Masters of Science and Epidemiology at Columbia, and that pinball finally settled here to UT Southwestern here in Dallas which I am very happy to make my second home. Mikkael Sekeres: That's great. I will say just for our listeners you've been a superstar since the moment you were a resident. It's been a real treat for me to get to know you over the years. Adeel Khan: Thank you so much. Mikkael Sekeres: Can you tell us a little bit about your own story as a writer? You're a good writer. We get submissions from some really good writers every single week. It's a real privilege to be an editor for the Art of Oncology section and it's always reinvigorating to me to see how many good writers there are in medicine. How did you start your journey as a writer and how long have you been writing reflective narrative pieces? Adeel Khan: I would say if I went back to let's say high school, you know, people tend to be divided into kind of like the sciency types versus the literary arts types and you're kind of an either/or, you know, you didn't really have as much crossover then. But you know, I actually didn't mind when we had an essay due and I liked writing back then, and when I entered college I did a minor in English because I actually did enjoy that and I just liked the idea of being able to put your thoughts on paper in a way immortalizing them. Adeel Khan: And then as I sort of pursuing medicine more and more, publishing is really- it has all kinds of flavors to it and scientific publishing is obviously what has been emphasized, but you know, there's so many things to talk about within medicine. There's the science and the art of the field, and as I've moved along, I've written different pieces focusing really on patient stories and interactions. And I think my motivation has always been that as I have gotten particularly nowadays increasingly busy, I've had the fortune and misfortune of becoming more and more busy, it's easy to lose the opportunity to really connect with people that makes what we do meaningful. And so in those times when you know, and they can be rare, but when you really get to connect with someone in front of you who you're helping to care for, it's really refreshing and it's rejuvenating and I've tried to keep that with me as long as I can as I've gone through my journey. Mikkael Sekeres: There's a lot of jumping off points from what you just said, Adeel. I wonder if I can start with do you consider yourself an English major who's good at science or do you consider yourself a scientist who's a good writer? Adeel Khan: I think I'm too humble to say either. I think I was really a science major who just happened to like writing and reading and kept that as a part of myself. Mikkael Sekeres: Because I think there are a cadre of doctors who are actually English majors and have learned to turn science into storytelling and that's their entrée into science and medicine. I remember I talked for a while with David Scadden about this. He's a brilliant translational scientist who's based at Mass General who also teaches a writing course to the Harvard undergrads and who was an English major when he was an undergrad at Case Western. We've talked about this, about how there are people, I'll include myself in this, who just think different, who probably have these liberal arts brains and they figured out a way to convert science into a way a liberal arts person can understand it. Adeel Khan: Yeah, I mean narrative medicine has been I think around all along and it has only kind of been recently named as a field, but I mean it very much speaks to that that there's so much more than just G proteins in medicine. Mikkael Sekeres: I'm thrilled to hear that by the way. You mentioned you were an English minor. Are there particular writers who are an influence on you or can you talk about what's the most recent book or article you've read? Adeel Khan: Oh, that is a great question. Paulo Coelho is someone I've liked for a long time, The Alchemist. I really liked it because I read it after I had lived in Egypt. I lived in Egypt between college and med school as a study abroad program, and I had actually been to the Faiyum Oasis where the protagonist in that story ends up. And so it was just a fascinating story to me that I could trace some of the steps that are discussed in the book and it's so much- it's a story about self discovery which at that phase of life that I was in was you know, very much a theme of my own life. And so that's one that definitely stands out in my head. Mikkael Sekeres: Do you think reading pieces outside of medicine makes you a better scientist? Adeel Khan: I think absolutely. I think it makes you a better human being. In some ways I lament that so much of what I do reading now is so much just about what's in the field, what's new in myeloma, what's new in hematology oncology and I sort of miss the escape to reading other things and being able to pursue it. And even broader than just what a novel really offers. I mean, I grew up reading comic books too and I've always loved superheroes and fiction whether it's Star Wars and other things. And really they're just stories and the medium- there might be connotations whether it's a comic book or a or a novel, but they're just different mediums, but the fact that they're just stories is fundamental. I actually think to myself that it's so fascinating that the earliest piece of writing that we've really retained as human beings is we believe, the Epic of Gilgamesh, which is really a story of a superhero when you think about it, you know, and it's it's fiction, it's phantasmic in so many ways. But it speaks to how stories are just vital as people. Mikkael Sekeres: And what is it about graphic novels or my kids now of course call them graphic novels. We're not allowed to call them comic books. Adeel Khan: As they've been renamed, yeah. Mikkael Sekeres: What is it about graphic novels or comic books or the story of a hero that appeals to us in medicine? Adeel Khan: I think it's in some ways a parable of what we're doing. There's something so powerful and fundamental about this idea of good-evil and we can rename it in different ways, but that you're trying to overcome something that's an issue, an obstacle. And when you think about what we do in- particularly in oncology, that's very much what we're trying to do. We're trying to overcome an illness, a disease, to try to help the person in front of us. And it has different aspects to it. It could be someone pursuing something in a lab, it can be treating someone in front of you in clinic, but that simple dichotomy of there's something good about what you're doing because there's something bad in front of you is just the fundamental that runs through it all. Mikkael Sekeres: It's fascinating. I wonder if 30, 40, 50 years ago people would have said, “Oh, it's because the doctor is the hero,” but we don't view ourselves that way anymore. The patient is the hero. I love how you posit this as a good versus evil, the evil of course being cancer and the good everything that our patients do and that we try to to help to do to overcome that. Adeel Khan: For sure. Mikkael Sekeres: You wrote a really great essay about a woman who was a patient of yours. Can you tell me a little bit about what inspired you this time to make this connection and to write about this woman? Adeel Khan: Within the past year or so as I had been just really- the fortune and misfortune of getting busier, I lamented that I just wasn't able to spend as much time with patients in the way that I used to. One of the beauties of medical school and you know, to some degree residency and certainly fellowship is that you just have a little bit more time as a trainee, student and trainee where you can really bond with your patients I think a little bit more. And so in trying to kind of refresh my motivation, I was thinking about just kind of randomly some stories that I've kept in the back of my mind and this patient's story is one that stood out to me as I was recalling things. It was so fascinating to me because she had the disease which I now focus on. And the way that she viewed it and the way that she viewed it as a part of her life was just so different than what I think most people think of. And in that way it was very revitalizing that her focus in her life was part of a broader theme of the way that I think she viewed society. And this was just one piece of her own part of that much, much larger puzzle. Mikkael Sekeres: You really write lovingly about her and about how meaningful her context was in how you cared for her and what her experience was in the medical system. I wonder if I can read a little bit of what you wrote because it really did grab me as well. I'm going to start out by quoting you where you say, “Outwardly, I had little in common with her. As a young South Asian man growing up in times more conscious of racial injustice, I was far removed from these historical crimes. Though I learned of them during my education, I did not internalize their impact on the patients in front of me in clinic. But through her, I came to comprehend just how scarring and enduring these events can be and how they can rob someone of trust.” Wow, there's a lot there. Could you start with what was your perspective as a young South Asian man growing up in Oklahoma and what your view was of racial injustice compared to what her experience was of racial injustice? Adeel Khan: Yeah, I have to admit I don't know that I thought that much of it back then and I think that that's part of what it is. You know, being someone who was South Asian, I'm Pakistani, I have Indian roots, and coming into American history and as we learned about it there's so much about slavery and the theme of slavery unfortunately and and the struggles that enslaved peoples have. And you know, as a relatively recent immigrant, I didn't see myself in that narrative. I didn't see myself in that historical reality. But I knew about it intellectually, you know, I knew about the Tuskegee Syphilis Experiments, you know, I learned about all these things and and you learned about how atrocious so much of it is. But again, not being so directly connected, I did not put myself in that same role as someone to view it so close to myself. I will say it hit a little bit more after 9/11 when you know, I was randomly stopped at airport security a little bit more often in those days and again, I think that speaks to racial injustices, you know, I was certainly profiled looking back then, I've been held by TSA in the past, but even that is very minor compared to what African Americans have dealt with here. And this patient in just kind of sharing her tidbits during our time together, I was not directly asking her so much of this. She was really offering a lot of it to me as we would talk and she would be very generous in sharing parts of her story. And over time I kind of understood the broader narrative of her life. You know, it was clear how much of all that was actually in the forefront of her head. Adeel Khan: And I think she might have been a little bit more unique in the way that she kept it there, but she was hyper vigilant of issues of society and the roots that brought a given society to where it is here. I kind of got to know her, this is during the COVID pandemic and this was after the injustice of what happened to George Floyd and so it was a theme that I think people were talking about more and so I think she felt comfortable in saying really what was quite a bit that was stewing in the back of her head seemingly at all times. Mikkael Sekeres: It's so interesting you talk about what you endured after 9/11 as being, I'm going to quote you now, “minor” compared to what she's been through, but even a minor affront like that can really compromise your trust. You write about her, “As a Black woman from the deep South, she had grown up learning how to navigate a healthcare system that did not always believe her.” Can you expand on that a little bit? How is it that the healthcare system didn't believe her and what can we do going into interactions with patients from different backgrounds where we're incorporating that there's a compromise of trust and we have to make up for that? Adeel Khan: Yeah, and I think you know, it's so unfortunate that so many people have stories like this where, in her case really it was back pain that was her presenting symptom. This is long before she knew me. And she'd had the back pain for quite some time, but being an older woman, she was in her 70s at that time, she was not in phenomenal health for other reasons. It sounds like she was just kind of ignored, told that it was old age, tendon changes, she did not have meaningful imaging for some time. When she finally did after seeing a slew of different providers, that's when it was revealed like there's something more significant here. And then when you kind of piece that a little bit retrospectively and I think she certainly sensed this and I did when I- hindsight's always 20/20, when I looked through things, it's like, well, this probably could have been caught much earlier. It's just that no one really I think listened to what she was speaking to with her pain and the gravity that was actually behind it. And it just speaks to the fact that I think we have to be more thoughtful in what we take away from patients and not to ignore even small comments because they might be revealing of something much bigger behind them. Mikkael Sekeres: You quote her, you have some really great quotes in your essay where you just listen to what she says and transcribe it because what she says is very meaningful. And one of the quotes you provide from her is, “They don't hear pain the same when it comes from someone like me.” Wow. “When it comes from someone like me,” someone like her, how was it that people weren't hearing her description of pain, something that was different that was going on in her body and how can we be more attentive to people when they complain about things like pain? Adeel Khan: It's unfortunate that there's even known data to show how depending upon a patient's melanin content in their skin, how likely they are to get pain medications and what happens to them is different and this is an unfortunate example of that where I think she just wasn't heard properly. And so it wasn't addressed properly and she was not shy about saying that. I mean I think she sensed that. She was very clear in feeling that herself and in wanting to have better care, she was still prevented and hence why she had to go from provider to provider. Mikkael Sekeres: You've lived in a bunch of different places in the country. I mean, following your path, you've been in Oklahoma, you've been in Michigan, Ohio, Massachusetts, and now Texas. Do you think that we as providers have to have different levels of sensitivity depending on where in the country we're practicing and how some of our patients' trust in healthcare may have been compromised in those different parts of the country? Adeel Khan: I think absolutely. I mean this particular patient was from Alabama which has a heavy history that she was again very aware of and for those of us reading history books are also very aware of too. And it's interesting how, while the U.S. is in some ways- has some aspects that are monolithic, but it's very much not so. It's very patchy and people are different, you know, if I take one theme that we're talking about here is obviously racial injustice, but if you take something like obesity, you know, prevalence rates are very different throughout the country and attitudes surrounding it are also very different. And I think we do- ought to be mindful that in treating the patient in front of us, it's not done without context. And so how they view their illness and their situation is going to be different depending upon the state, depending upon the city, depending upon actually even the era that they grew up in. So I would say now, if you took actually a similar patient, but you put her in a very modern context post-year 2000, she's likely to have different feelings of the situation around her than someone who was born in this case in the 1940s. And that just speaks to the fact that circumstances change and we should be recognizing that as providers, even though it's not always easy to. Mikkael Sekeres: Well, it just emphasizes how very important it is to know the history of the place where we practice and how it's affected our patients' perceptions of healthcare and trust and being cared for, particularly now as there's such a movement to whitewash that history and eliminate it from major institutions like the Smithsonian. It has been such a pleasure to have Adeel Khan here. He is Assistant Professor of Medicine, Public Health at UT Southwestern in Dallas and wrote just a great JCO article called “A Fight Bigger Than Myeloma.” Adeel, thank you so much for submitting your article and for joining us today. Dr. Adeel Khan: Thank you so much for having me. It's been a pleasure. Mikkael Sekeres: If you've enjoyed this episode, consider sharing it with a friend or colleague or leave us a review. Your feedback and support helps us continue to have these important conversations. If you're looking for more episodes and context, follow our show on Apple, Spotify, or wherever you listen and explore more from ASCO at ASCO.org/podcasts. Until next time, this has been Mikkael Sekeres for JCO Cancer Stories: The Art of Oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Show Notes Like, share and subscribe so you never miss an episode and leave a rating or review.  Guest Bio: Dr Adeel Khan is an Assistant Professor of Medicine and Public Health at UT Southwestern.

In this special series on Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated steatohepatitis (MASH) our host, Dr. Neil Skolnik will discuss Epidemiology, Importance, Screening and treatment of MASH. This special episode is supported by an independent educational grant from Boehringer Ingelheim. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Jay Shubrook, D.O., Professor and Diabetologist in the Department of Clinical Sciences and Community Health At Touro University California College of Osteopathic Medicine Selected references: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care 2025;48(7):1057–1082  

People under 50 are experiencing higher risk of some cancers. While overall cancer rates are declining, the incidence of 14 cancer types have increased in younger people. Why? It could be related to lifestyle choices, environmental factors, or an individual's genetics. In this episode, host Samantha Laine Perfas speaks with global cancer trend expert Tim Rebbeck, oncologist Kimmie Ng, and epidemiologist Tomotaka Ugai about how people under 50 can best mitigate their cancer risk.

In this episode, I'm talking with Medha Kaul a research data analyst in the Division of Epidemiology at Mayo Clinic about her job and the research she is doing!

About this episode: For centuries, public health has seen invisible killers, believed in the power of community interventions, and created better health outcomes across the globe. In this episode: Former CDC director Tom Frieden explains how to tackle today's biggest health challenges and previews his new book, “The Formula for Better Health: How to Save Millions of Lives—Including Your Own”. Guest: Dr. Tom Frieden, MPH, is the president and CEO of Resolve to Save Lives. He previously served as the director of the CDC and is the author of “The Formula for Better Health: How to Save Millions of Lives—Including Your Own”. Host: Dr. Josh Sharfstein is distinguished professor of the practice in Health Policy and Management, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: The Formula for Better Health: How to Save Millions of Lives—Including Your Own—Penguin Random House A former CDC director's guide to seeing and stopping threats to America's health—STAT Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Problem gambling - it's on the rise here in Rhode Island but it's not just happening at the casino or the racetrack. Online forms like sports betting have become a powerful draw for many. How does one know when it's become a problem? What are the warning signs? In this episode, Dr. Samantha Rosenthal, a professor of Health Science at Johnson & Wales University and Adjunct Professor of Epidemiology at Brown School of Public Health joins Dr. Chan to talk about what to look out for, who is most at risk, and much more. 

This week we're joined by Adele Houghton of the Harvard School of Public Health and Carlos Castillo-Salgado of the Johns Hopkins Bloomberg School of Public Health to discuss their new book Architectural Epidemiology: Architecture as a Mechanism for Designing a Healthier, More Sustainable, and Resilient World. We chat about how to connect the social and architectural determinants of health before projects get off the ground in order to create more healthy neighborhoods. +++ Get the show ad free on Patreon! Follow us on Bluesky, Threads, Instagram, YouTube, Flickr, Substack ... @theoverheadwire Follow us on Mastadon theoverheadwire@sfba.social Support the show on Patreon http://patreon.com/theoverheadwire Buy books on our Bookshop.org Affiliate site!  And get our Cars are Cholesterol shirt at Tee-Public! And everything else at http://theoverheadwire.com

Join the October Menopause Challenge: https://drgabriellelyon.com/forever-strong-menopause-challenge/Pre-Order The Forever Strong PLAYBOOK and receive exclusive bonuses: https://drgabriellelyon.com/playbook/Want ad-free episodes, exclusives and access to community Q&As? Subscribe to Forever Strong Insider: https://foreverstrong.supercast.comDescriptionIn this critical episode, Dr. Gabrielle Lyon sits down with pediatrician Dr. Joel Warsh—known to many as "Dr. Gator"—to confront the most concerning trends in children's health. Dr. Warsh, author of A Shot and a Hard Place, reveals the staggering rise of chronic disease and autism in children, arguing that it's a crisis that demands a deeper, more open conversation.This is a brave and necessary discussion that moves beyond political rhetoric and into the science. Dr. Warsh, an epidemiologist, offers a candid perspective on the vaccine debate, challenging the notion that the "science is settled." He reveals the surprising truth about what research has and hasn't been done on the long-term effects of the cumulative vaccine schedule.This episode is a must-listen for any parent who wants to be empowered with the knowledge to make informed decisions for their family and understand the true impact of our food system, environmental exposures, and sedentary lifestyles on the next generation.Chapter Markers0:00 - The Chronic Disease Epidemic in Kids2:51 - The Vaccine Debate: Risks vs. Benefits4:06 - A Pediatrician's Take on the Newborn Hep B Vaccine12:50 - The Alarming Rise in Autism Rates15:09 - The Missing Research on the Vaccine Schedule19:30 - How to Navigate Conflicting Information from RFK Jr.40:01 - The Role of Environmental Toxins in Chronic Illness44:50 - The Food System & The Epidemic of Childhood Obesity50:11 - Screen Time & The Sedentary Child55:50 - The Presidential Fitness Test Debate1:00:03 - Safe Workouts for Kids & The Importance of Movement1:11:31 - Final Thoughts on CDC, Personal Choice & The Road AheadWho is Joel Gator:Joel Warsh is a Board-Certified Pediatrician in Los Angeles, California who specializes in Parenting, Wellness and Integrative Medicine. He grew up in Toronto, Canada and completed degrees in Kinesiology, Psychology and Epidemiology and Community Health before earning his medical degree from Thomas Jefferson Medical College. He completed his Pediatric Medicine training at Children's Hospital of Los Angeles (CHLA) and worked in private practice in Beverly Hills before founding his current practice, Integrative Pediatrics and Medicine Studio City, in 2018.Dr. Gator has published research in peer-reviewed journals on topics including childhood injuries, obesity and physical activity.He has been featured in numerous documentaries, films, summits, podcasts and articles including CBS, Fox, LA Parent, Washington Post, MindBodyGreen, and many others.He is also the founder of the Parenting Masterclass Platform Raising Amazing which can be found at RaisingAmazingPlus.comDr. Joel Gator may be best known for his popular Instagram DrJoelGator where he offers weekly parenting and integrative pediatric support.He is a...

Omari Richins, MPH of Public Health Careers podcast talks Tosin Ogunsola, MPH and Tobi Dare, MPH. They are co-creators of the Health Whiz game. In this conversation, Tobi Dare and Tosin Ogunsola, co-founders of Health Whiz, share their journey in creating a board game aimed at improving public health literacy. They discuss their backgrounds in public health, the inspiration behind Health Whiz during the COVID-19 pandemic, and the importance of gamification in health education. The duo highlights the positive community response to their game, the mechanics of gameplay, and their long-term goals for expanding its reach. They also reflect on their professional experiences, the lessons learned in co-founding a business, and offer advice for aspiring public health professionals.

“It's 5pm and your Consultant (attending) has headed off home. A patient arrives in the resuscitation room blood spurting from a stab wound in the armpit. Join Roisin – a junior Major Trauma fellow, Prash – a surgical trainee, Max – a senior trauma surgery fellow, and Chris – a Consultant trauma surgeon, as we talk through decision making from point of injury to aftercare in this challenging trauma surgical case”. • Hosts: Bulleted list of host names, including title, institution, & social media handles if indicated 1.     Mr Prashanth Ramaraj. General Surgery trainee, Edinburgh rotation. @LonTraumaSchool 2.     Dr Roisin Kelly. Major Trauma Junior Clinical Fellow, Royal London Hospital.  3.     Mr Max Marsden. Resuscitative Major Trauma Fellow, Royal London Hospital. @maxmarsden83 4.     Mr Christopher Aylwin. Consultant Trauma & Vascular Surgeon and Co-Programme Director MSc Trauma Sciences at Queen Mary University of London. @cjaylwin • Learning objectives: Bulleted list of learning objectives. A)    To become familiar with prehospital methods of haemorrhage control in penetrating junctional injuries. B)     To recognise the benefits of prehospital blood product resuscitation in some trauma patients. C)     To follow the nuanced decision making in decision for CT scan in a patient with a penetrating junctional injury. D)    To describe the possible approaches to the axillary artery in the context of resuscitative trauma surgery. E)     To become familiar with decision making around intraoperative systemic anticoagulation in the trauma patient. F)     To become familiar with decision making on type of repair and graft material in vascular trauma. G)    To recognise the team approach in holistic trauma care through the continuum of trauma care. • References: Bulleted list of references with PubMed links. 1.    Perkins Z. et al., 2012. Epidemiology and Outcome of Vascular Trauma at a British Major Trauma Centre. EJVES. https://www.ejves.com/article/S1078-5884(12)00337-1/fulltext 2.    Ramaraj P., et al. 2025. The anatomical distribution of penetrating junctional injuries and their resource implications: A retrospective cohort study. Injury. https://www.injuryjournal.com/article/S0020-1383(24)00771-X/ 3.    Smith, S., et al. 2019. The effectiveness of junctional tourniquets: A systematic review and meta-analysis. J Trauma Acute Care Surg. https://journals.lww.com/jtrauma/abstract/2019/03000/the_effectiveness_of_junctional_tourniquets__a.20.aspx 4.    Rijnhout TWH, et al. 2019. Is prehospital blood transfusion effective and safe in haemorrhagic trauma patients? A systematic review and meta-analysis. Injury. https://www.injuryjournal.com/article/S0020-1383(19)30133-0/ 5.    Davenport R, et al. 2023. Prehospital blood transfusion: Can we agree on a standardised approach? Injury. https://www.injuryjournal.com/article/S0020-1383(22)00915-9. 6.    Borgman MA., et al. 2007. The Ratio of Blood Products Transfused Affects Mortality in Patients Receiving Massive Transfusions at a Combat Support Hospital. J Trauma Acute Care Surg. https://journals.lww.com/jtrauma/fulltext/2007/10000/the_ratio_of_blood_products_transfused_affects.13.aspx 7.    Holcomb JB., et al. 2013. The Prospective, Observational, Multicenter, Major Trauma Transfusion (PROMMTT) Study. Comparative Effectiveness of a Time-Varying Treatment With Competing Risks. JAMA Surgery. https://jamanetwork.com/journals/jamasurgery/fullarticle/1379768 8.    Holcomb JB, et al. 2015. Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma. The PROPPR Randomized Clinical Trial. JAMA. https://jamanetwork.com/journals/jama/fullarticle/2107789 9.    Davenport R., et al. 2023. Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury. The CRYOSTAT-2 Randomized Clinical Trial. JAMA. https://jamanetwork.com/journals/jama/fullarticle/2810756 10.   Baksaas-Aasen K., et al. 2020. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. ICM. https://link.springer.com/article/10.1007/s00134-020-06266-1 11. Wahlgren CM., et al. 2025. European Society for Vascular Surgery (ESVS) 2025 Clinical Practice Guidelines on the Management of Vascular Trauma. EJVES. https://esvs.org/wp-content/uploads/2025/01/2025-Vascular-Trauma-Guidelines.pdf 12. Khan S., et al. 2020. A meta-analysis on anticoagulation after vascular trauma. Eur J Traum Emerg Surg. https://link.springer.com/article/10.1007/s00068-020-01321-4 13. Stonko DP., et al. 2022. Postoperative antiplatelet and/or anticoagulation use does not impact complication or reintervention rates after vein repair of arterial injury: A PROOVIT study. Vascular. https://journals.sagepub.com/doi/10.1177/17085381221082371?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Grain Report Expectations BRD Treatment Studies Wet or Dry Weather Ahead?   00:01:05 – Grain Report Expectations: K-State grain economist Daniel O'Brien begins today's show by discussing the upcoming USDA Grain Stock and Small Grains report expectations, as well as a positive outlook for corn exports. Daniel O'Brien on AgManager.info   00:12:05 – BRD Treatment Studies: The show continues with David Renter, director of the Center for Outcomes Research and Epidemiology at K-State, as he explains research he and his team have done looking into treatment choices for Bovine Respiratory Disease. Center for Outcomes Research and Epidemiology at K-State   00:23:05 – Wet or Dry Weather Ahead?: Chip Redmond, K-State meteorologist, wraps today's show with his weather forecast, where he expects warmer than normal temperatures and steady weather.     Send comments, questions or requests for copies of past programs to ksrenews@ksu.edu.   Agriculture Today is a daily program featuring Kansas State University agricultural specialists and other experts examining ag issues facing Kansas and the nation. It is hosted by Shelby Varner and distributed to radio stations throughout Kansas and as a daily podcast.   K‑State Research and Extension is a short name for the Kansas State University Agricultural Experiment Station and Cooperative Extension Service, a program designed to generate and distribute useful knowledge for the well‑being of Kansans. Supported by county, state, federal and private funds, the program has county Extension offices, experiment fields, area Extension offices and regional research centers statewide. Its headquarters is on the K‑State campus in Manhattan

Dr. Becky Smith, Associate Professor of Epidemiology, University of Illinois College of Veterinary Medicine, joins Lisa Dent to discuss the risk of an tick invasion in Illinois. Among the many tick species in Illinois, there are three that carry diseases. Dr. Smith shares what steps someone should take after finding a tick embedded in your […]

In this special episode on Obstructive Sleep Apnea our host, Dr. Neil Skolnik will discuss treatment of OSA. In Part 1 we discussed an overview of OSA, in Part 2 we discussed making the diagnosis, Part 3 was treatment, and in Part 4 we bring it all together with a case to explore clinical decision making for OSA. This special episode is supported by an independent educational grant from Lilly. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Dr. Sanjay Patel, M.D, Professor of Medicine, Epidemiology, & Clinical and Translational Science, and Director of the Center for Sleep and Cardiovascular Outcomes Research; Medical Director of the Comprehensive Sleep Disorders Program, University of Pittsburgh Medical Center Susan Kuchera, M.D. - Clinical Associate Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University and Program Director of the Family Medicine Residency at Jefferson Health Abington. Selected references: Diagnosis and Management of Obstructive Sleep Apnea - A Review. JAMA. 2020;323(14):1389-1400 Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193-1205  

Send us a textIn this episode, host Mighty Fine is live with attendees at the Safe States 2025  Annual Conference held virtually this year. Hear how they are "Rising Up and Branching Out" in their injury and violence prevention work through networking, attending sessions and getting involved during the three day conference held September 9-11 online.Guests include:Lisa Roth, Deputy Director, University of Iowa Injury Prevention Research CenterDilenny Roca, Program Manager, Department of Epidemiology, Columbia University Medical CenterStacey Pinto, Trauma Injury Prevention & Outreach Coordinator at Good Samaritan University HospitalScott Proescholdbell, Epidemiologist/Manager at North Carolina Division of Public HealthAmy Schlotthauer, Founding Principal, AES ConsultingJoanne Miles-Holmes, Injury Prevention Program Administrator, New Hampshire Department Health & Human ServicesTracy Mehan, Director of Research Translation & Communication, Center for Injury Research and Policy at Nationwide Children's HospitalVictoria Broussard, Senior Project Officer, Health Resources in ActionLynnsey O'Rourke, Program Coordinator, Safe States AllianceJessica Ritter, Safe Kids PA Office Coordinator, American Trauma Society, Pennsylvania DivisionMusical transition credit: Pixabay "Conga-man Groove" by Miyagisama

☀️ Walking on Sunshine? Rethinking Our Relationship with the Sun!

In 2023, we released 2 episodes on obstructive sleep apnea (OSA) and adverse pregnancy. Now, on September 16, 2025, a new publication from JAMA Network Open adds more insights to disturbed sleep and adverse pregnancy outcomes. How does insomnia affect pregnancy? And is there any data on night shift work and its altered circadian rhythms on adverse pregnancy outcomes? Listen in for details. 1. Ross N, Baer RJ, Oltman SP, et al. Ischemic Placental Disease and Severe Morbidity in Pregnant Patients With Sleep Disorders. JAMA Netw Open. 2025;8(9):e2532189. doi:10.1001/jamanetworkopen.2025.321892. Cai C, Vandermeer B, Khurana R, et al. The Impact of Occupational Shift Work and Working hours during Pregnancy on Health Outcomes: a systematic Review and Meta-Analysis.American Journal of Obstetrics and Gynecology. 2019;221(6):563-576. doi:10.1016/j.ajog.2019.06.051.3. Dominguez JE, Cantrell S, Habib AS, Izci-Balserak B, Lockhart E, Louis JM, Miskovic A, Nadler JW, Nagappa M, O'Brien LM, Won C, Bourjeily G. Society of Anesthesia and Sleep Medicine and the Society for Obstetric Anesthesia and Perinatology Consensus Guideline on the Screening, Diagnosis, and Treatment of Obstructive Sleep Apnea in Pregnancy. Obstet Gynecol. 2023 Aug 1;142(2):403-423. doi: 10.1097/AOG.0000000000005261. Epub 2023 Jul 5. PMID: 37411038; PMCID: PMC10351908.4. Kader M, Bigert C, Andersson T, et al . Shift and Night Work During Pregnancy and Preterm Birth-a Cohort Study of Swedish Health Care Employees. International Journal of Epidemiology. 2022;50(6):1864-1874. doi:10.1093/ije/dyab135.STRONG COFFEE PROMO: 20% Off Strong Coffee Companyhttps://strongcoffeecompany.com/discount/CHAPANOSPINOBG

Host Dr. Shannon Westin and guest Dr. Hani Babiker discuss the JCO article "Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study." TRANSCRIPT TTFields in Locally Advanced Pancreatic Adenocarcinoma Dr. Shannon Westin: Hello everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth with manuscripts that have been published in the Journal of Clinical Oncology. I am your host, gynecologic oncologist Shannon Westin, social media editor at the JCO, and just excited to be here to learn today about pancreatic cancer. None of our participants have conflicts of interest related to this podcast, and it is my honor to introduce Dr. Hani Babiker. He is an associate professor of medicine, consultant in oncology at the Mayo Clinic in Jacksonville, Florida. Welcome, Dr. Babiker. Dr. Hani Babiker: Hi, Dr. Westin. Thank you for the great opportunity to discuss our trial, and thank you for having me here. I really appreciate it, and I am excited. Dr. Shannon Westin: All right, so are we. So we are going to be talking about “Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: A Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.” This was simultaneously published and presented in the JCO and at the annual meeting of ASCO on 5/31/2025. So, let's level set. Can you speak to us just a little bit about pancreatic cancer? What is the survival, and what is the typical treatment for locally advanced disease? This gynecologic oncologist has not kept up in this field. Dr. Hani Babiker: Absolutely, Dr. Westin, and thank you for that question. Pancreatic adenocarcinoma is a lethal cancer. When I first started my career, the 5-year survival, per the Surveillance, Epidemiology, and End Results, was at 4.5%. I always, whenever I was giving talks, say that I really hope that I will see it in the double digit. Now, the 5-year survival for all pancreatic adenocarcinoma is 13.3%. And the 5-year survival, and although it is a double digit, I still hope that I will see it in a higher double digit in the future. It is even worse in patients with metastatic cancer, about 3% 5-year survival for metastatic pancreatic cancer. It is a dismal diagnosis. I really hope in the future we will find a better therapeutic approach to this lethal cancer. Dr. Shannon Westin: Yes, I just lost a very dear friend and colleague to this disease, so I completely agree with you. Well, now that we are settled kind of with the basics here, I would love to talk a little bit about kind of the primary piece of this intervention, the Tumor Treating Fields. So, how does this work? And what diseases has it gotten indications in as yet? Dr. Hani Babiker: Absolutely. So, Tumor Treating Fields is alternating frequency electrical fields that have been studied preclinically and shown that it abrogates cancer cell proliferation. Earlier on, we knew that it inhibits polymerization of tubulin, and hence, it affects cancer cells from proliferating. Later, we are learning that there are multiple mechanisms of action. It affects permeability, allowing for better drug delivery. It also inhibits cancer cell proliferation through affecting autophagy mechanisms that pancreatic cancer cells will use for proliferating and becoming more aggressive. There is also some early data preclinically in colorectal cancer cell lines and lung cancer cell lines and in vivo models showing that it potentially could activate the microenvironment to make it more pro-immunogenic. We recently published papers showing that it could also affect the nanomechanical properties of the tumor microenvironment within pancreatic cancer, hinting towards affecting, potentially, the stroma. So, there are multiple mechanisms to Tumor Treating Electric Fields. It is a new, novel therapeutic approach. Sometimes when I speak with my trainees, I say, "Well, we have surgery, we have radiation and chemotherapy, and this is something new." Tumor Treating Fields initially was studied in refractory GBM and got an indication there. Subsequently, frontline treatment of GBM in a randomized clinical trial, and then malignant pleural mesothelioma and non-small cell lung cancer. We have studied it in pancreatic cancer. Dr. Shannon Westin: I don't think I have ever heard it described so perfectly. That was brilliant. So thank you, and I hope everyone listening knows that you just got a masterclass on this mechanism. You know, they dabbled in it a little bit in ovarian cancer and it didn't quite make the grade, so I was a little definitely disappointed. But very excited about the data we're going to talk about today. So let's get into the PANOVA-3 study. Can you highlight the overall design and also the key eligibility criteria that would be helpful for our listeners? Dr. Hani Babiker: Absolutely. So, it started off with preclinical work in pancreatic cancer showing Tumor Treating Fields with chemo abrogate cancer cell perforation. It led to a trial, the PANOVA-2 trial, that was run in Europe that showed efficacy for OS and PFS in patients with locally advanced pancreatic cancer, which included metastatic and locally advanced pancreatic cancer, more so in locally advanced that led to the PANOVA-3 trial, which was an international, global study. This was in more than 190 centers, 20 countries in Latin America, North America, Europe, and Asia. It was a randomized trial. Patients were randomized 1 to 1 to either chemotherapy with gemcitabine plus nab-paclitaxel per drug label. The other arm was with Tumor Treating Fields at 150 kHz for a recommendation for patients to wear it 18 hours per day. The primary end point of the trial was OS, overall survival. The secondary end point included other efficacy landmarks such as local PFS, pain control, quality of life, and safety. And there was a post hoc that looked at distant PFS. Dr. Shannon Westin: That's a pretty common secondary end point in pancreatic studies of looking at the pain-free interval. I thought that was really brilliant because, you know, I think in gyn cancers, we see resolution of symptoms as being a really big deal, but it's not necessarily something that we always look at. So I thought that was really nice that you included that. Okay, talk to us a little bit about the population. So, the population that actually got treated in PANOVA-3 is pretty generalizable to what people are treating in the clinic. Dr. Hani Babiker: So, in pancreatic cancer, unfortunately, most of our patients present, approximately 80%, with metastatic disease. Local is divided to resectable, borderline, and locally advanced. We studied this trial, a randomized trial, in locally advanced and unresectable, which is really an unmet need. Most of our patients with locally advanced and unresectable are grouped up with other trials in the metastatic setting without a focus on locally advanced and unresectable, save for a few trials. This year, a trial that we were looking for for a long time, the LAPLACE trial, unfortunately, that we were very excited about, this is a molecule that targeted connective tissue growth factor, that showed earlier efficacy in a randomized trial, did not meet up the median OS end point. And hence, PANOVA-3 is the first trial in locally advanced and unresectable that did meet its primary end point. So, it's a very unmet need in locally advanced and unresectable. A lot of the times, our patients in clinic are treated with frontline chemotherapy that was studied in metastatic disease and locally advanced and unresectable, which include either FOLFIRINOX, NALIRIFOX, or gemcitabine/abraxane. I do have in my clinic multiple patients that would stay on the regimen for such a long time, and then we would have to devise a mechanism of maintenance, although this is not studied really in details, either with capecitabine or dropping the oxaliplatin to continue FOLFIRI. And then we also approach chemoradiotherapy. So the trial was in a disease in pancreatic cancer that really is an unmet need. So the inclusion criteria included a patient with locally advanced and unresectable. These were done at multiple centers. Most of them academic centers were discussed at the tumor board, and if it's unresectable, they will be meeting specific metrics of appropriate liver function tests, kidney function tests, and blood counts. We excluded patients that obviously had, given that these are electric fields, patients that have, for example, stimulators or pacemakers, knowing that this could potentially affect some of these devices. But for the most part, it was locally advanced and unresectable patients with a very good performance status and good counts. Dr. Shannon Westin: That's great. I think everyone's excited to hear about the primary outcome of overall survival. What did you find, and how does it compare to some of the recent trials? Dr. Hani Babiker: We're very excited that it did meet its primary end point of median overall survival. It was very exciting knowing that a lot of us were disappointed a little bit of some of the trials that were presented at ASCO GI, such as the LAPLACE trial that I alluded to. Just before the presentation, the PRODIGE 29 trial that is in locally advanced and unresectable that randomized patients with locally advanced disease to either FOLFIRINOX or single-agent gemcitabine, allowing for a crossover, although it did meet its primary end point of PFS, there was no overall survival benefit. So that kind of got us a little bit disappointed, but having the PANOVA-3 trial being positive in median OS got us all excited. In addition, the 12-year overall survival rate was increased in both the intention-to-treat and modified intention-to-treat. The modified intention-to-treat were patients that have had at least one cycle of therapy with TTFields daily and/or one cycle with chemotherapy, which was gemcitabine plus nab-paclitaxel. There was a trend to improvement in PFS and local PFS, although that did not have statistical significance, but the 12-year PFS rate in both the intention-to-treat and modified intention-to-treat was significant. For me, as one of the investigators, that told me that there might be a specific biomarker that would tell me that patients could respond greater than others, more exceptional than others, given that 12-month PFS rate was improved. On a post hoc analysis, the distant PFS was improved with the intervention of Tumor Treating Fields with gemcitabine plus nab-paclitaxel. In addition, there was an improvement in global health status and quality of life in addition to pain-free survival, which is a strong hurdle in our patients with pancreatic adenocarcinoma that most present with significant abdominal pain. Dr. Shannon Westin: One of the other questions that I think has come up is around central review. So did you all use central review in this study? Dr. Hani Babiker: Most of the centers were academic centers. These were discussed in tumor boards, which included radiation oncologists and surgeons. I wanted to point out that it's very important to note that the primary end point was overall survival. So the primary end point was not PFS. Hence, the central review would help us, for example, with elaborating and making sure patients were actually locally advanced disease, but in a setting where the primary end point is overall survival, that was the key point of the clinical trial. This trial was discussed at academic centers, and all included tumor boards to decide if patients were locally advanced or not. In the trial, there was a good proportion of patients, or percentage, that had a CA 19-9 more than 1000. That could indicate that potentially there are a fraction of patients that actually had metastatic disease, micrometastatic disease. So that could hint towards why the median OS was slightly lower then in both arms when compared to, for example, the trial that was presented at ASCO GI, the LAPLACE trial. However, having said that, we were very excited about the trial. It was the first positive trial in locally advanced and unresectable to meet median OS survival. Dr. Shannon Westin: It's so awesome. So congratulations. Okay, so let's talk a little bit about your very detailed secondary end points because you had a lot of really prudent choices there. So anything that was interesting or informative in those end points? Dr. Hani Babiker: One major hurdle back we have for most of our patients with pancreatic adenocarcinoma, like I mentioned earlier, is pain. We try to approach it, obviously, with narcotics. If it doesn't work, we try to do celiac axis block interventionally, and that sometimes is successful and sometimes is not. So actually, to see the pain-free survival end point to be met was very exciting for us. And as for me, as a scientist that studies TTFields in clinic and lab as also to develop a mechanism and understanding really how that works. That was very important for us that in addition to chemotherapy, it improved pain-free survival or deterioration of pain. And most importantly, our patients with pancreatic cancer, this disease is very aggressive. It affects quality of life of patients. Patients feel fatigued, tired. It's a procoagulant tumor that causes clots and strokes, etcetera, marantic endocarditis. And one big problem we deal with when we're seeing patients in clinic is obviously that quality of life. Although data have shown with treatment, with frontline regimens, that quality of life improves with treatment and chemotherapy, it's actually great to see that that improvement happens early in addition to Tumor Treating Fields. The other interesting point was that it was not only pain and quality of life, but also digestive symptoms that are improved with this intervention, knowing that a lot of our patients do have pancreatic cancer, pancreatic exocrine insufficiency that affect also with digestion, and a lot of our patients have abdominal pain after eating and diarrhea. So it was interesting to see that also improved with the intervention. Dr. Shannon Westin: You have touched a little bit on some of the adverse events, kind of with the TT mechanisms, but I'd love to hear a little bit more detail around adverse events in general in this study, as well as specific AEs related to the Tumor Treating Fields. Dr. Hani Babiker: Absolutely. So when we compared both arms, there was a similar toxicity related to the regimen, mostly with chemotherapy, but in specifically to Tumor Treating Fields, there was a rash, and that included dermatitis and rash. Most of the side effects were grade 1 and grade 2. Grade 3 toxicities related to skin was less than 10%, approximately 7% to 8%, and hence did not affect many patients. But it was something to note, and it's something that in the future, when we develop a mechanism of treating patients to note early. We in our clinic have learned to treat patients in the clinical trial early with topical steroids to each patient, of shifting the arrays to mitigate some toxicity and rash. We do advise our patients in hot areas, we keep them aware that sweating, for example, can lead to higher conductivity of electrical fields with a predisposition for rash. So if there's an opportunity to stay in a little bit of a cold area, make sure that the arrays are shifted, use topical steroids early. If it's a significant rash, to hold treatment for at least 48 hours and speak to the investigators. And through these mechanisms, we have learned that we were able to mitigate the rash quite a bit. Dr. Shannon Westin: That's awesome. Thank you so much. Yeah, I'm, it's summer right now, and I think- I'm in Texas, you're in Florida, like we know. Okay, so I guess, again, you have been kind of touching on this, but I would love to know, like if in the quality-of-life assessments or if just in your discussions with patients, like how easy is this to use? How easy is the Tumor Treating Fields device to use, and what do patients really think? Dr. Hani Babiker: Absolutely. We have learned that whenever we speak with patients, it's always good to discuss with them briefly the science of it. A lot of patients would want to know if it's interventional, is that something that goes, is delivered percutaneously or not, and we explain that these are delivered through arrays that are through the skin. We always touch base with them about a lot of question I get about mechanism of action and then about compliance. So I think one important thing to note is that compliance with the use of the device is a lot of the question we'll get quite a bit. Patients know there's going to take an effort from them, and some of my patients enjoyed it because they felt like they also are fighting the disease by wearing the device. I have learned very quickly that having a team, surrounded by a team that knew how to mitigate some of the side effects and knew how to explain how to use the device helped quite a bit. And this included some of our nurses and our nurse practitioners and our clinical research coordinators who've done a wonderful job of showing these arrays actually to patients before they start on the trial, look at it, know how it works. The other point to know is that the sponsor provided Device Support Specialist, we call them DSS, they have been instrumental in helping us, helping the patients know how to use the device, how to use the generator, how to change the batteries, and that helped us conduct the trials and enroll very well. I would envision in the future with education and relying on the Device Support Specialist and having a team that knows how to use the device and mitigate some of the side effects will go a long way for patients to learn about this treatment. Many of the times our patients said while they are on the clinical trial felt like they are also being part of this team in applying the device and fighting the cancer. Dr. Shannon Westin: That's awesome. Well, I guess the bottom line. Is it ready for prime time? Is this something you are going to use for your patients in the clinic? Dr. Hani Babiker: Absolutely. In a disease that has poor prognosis, and we are trying our best to find new treatments to fight this cancer and treatment modalities, presenting patients with all the treatment options that are out there would be recommended. It's what I would do it for in my clinic. And you know, it's funny that I am mentioning that right now. I had a patient who was seen internationally asking about the trial and the device and had locally advanced and unresectable before they start frontline treatment. I do think that there is going to be an educational piece. Obviously, this is not a pill, it's not an intravenous chemotherapy that we're very well and accustomed to. And some of us in academic centers know it very well. I usually joke that whenever I am talking about it in pancreatic cancer, if there is a radiation oncologist in the room, they will be like, "Yeah, we know all about it. We have been treating patients with GBM over there." So a lot of the times, when we first went to trial, if I had any questions, I would call them and ask them. So from their perspective, they, because they use it as a standard of care in treatment of GBM, they develop significant expertise in it. I think in the GI world, specifically and with oncologists that treat pancreatic cancer and specifically oncologists in the community, learning about the device and how to use it, how to recommend it, how to mitigate side effects, will be hopefully for prime time in the future. Dr. Shannon Westin: That's great. Sounds like some real educational opportunities there. Well, this has been awesome. Thank you so much, Dr. Babiker. I mean, I learned a ton, and I wish that we could find a way to use this in gynecologic cancers, but really, really just want to commend you on the design of the trial and the success in this really devastating disease. So again, this was "Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: A Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study." And as always, I am your host, Shannon Westin. Please go check out our other offerings wherever you get your podcasts and have an awesome day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Dr. Babiker Disclosures Consulting or Advisory Role: Endocyte, Celgene, Idera, Myovant Sciences, Novocure, Ipsen, Caris MPI, Incyte, Guardant Health Speakers' Bureau: Guardant Health Research Funding:  Spirita Oncology, Novocure, AstraZeneca, JSI, Incyte, Qurient, HiFiBiO Therapeutics, Revolution Health Care, Elevation Oncology, Dragonfly Therapeutics, Zelbio, BMS, Mirati Therapeutics, Strategia        

In a time where we need hope and innovation more than ever, we asked 13 health leaders—all guests on this podcast—what they would do to reimagine health. Tune into the episode to hear what they shared (in order of appearance):David Zipper, Senior Fellow, MIT Mobility Initiative Maya Petersen, Professor of Biostatistics, Epidemiology and Computational Precision Health, UC Berkeley Kody Kinsley, Senior Policy Advisor, Johns Hopkins University (former Secretary of HHS in North Carolina)Theresa Cullen, Director of Public Health, Pima County, AZ Anne Zink, Lecturer & Senior Fellow, Yale School of Public Health (former Chief Medical Officer, AlaskaKaren DeSalvo, former Chief Health Officer, Google Palav Babaria, Chief Quality and Medical Officer, California Department of Health Care Services Jacey Cooper, President, Precision Health Strategies (former Medicaid Director in California)Pooja Mittal, Chief Health Equity Officer, Health NetNatalie Davis, Co-Founder and CEO, United States of CareSteve Downs, Co-Founder, Building H Katie Drasser, CEO, Rock HealthZoanne Clack, Executive Producer, Grey's Anatomy Connect With UsFor more information on The Other 80 please visit our website - www.theother80.com. To connect with our team, please email claudia@theother80.com and follow us on twitter @claudiawilliams and LinkedInSubscribe to The Other 80 on YouTube so you never miss our video extras or special video episodes.

"[Associations] are banking 60% of our revenue on four days out of the year - and only 20% of members engage.”If that statistic scares you, it should. While association events lead to both connection and revenue, associations are missing opportunities for their next big program by not thinking bigger.In this season finale of the Association RevUP Podcast, host Carolyn Shomali is joined by Marcus Maleck (Society for Clinical Research Sites), James Young (Product Community), David Upbin (Mortgage Bankers Association), and Letty Kluttz (Association for Professionals in Infection Control and Epidemiology). Together, they share real-world examples of how their associations discovered new association revenue opportunities by:Selling outcomes instead of productsExtending the life of events beyond “one and done”Simplifying and packaging offerings for membersResponding to market shifts with fresh solutionsIf you're looking to grow association revenue and create lasting member value, this episode will give you practical ideas you can apply right away.About Association RevUP: A PAR podcast that celebrates the stories of associations who are utilizing business to bring about real change in their industries. Episodes are less than 15-minutes, written and produced to keep you engaged, and full of actionable insights. Hosted by Carolyn Shomali.- ⁠⁠⁠VPC, Inc.⁠⁠⁠, the boutique production company PAR trusts with our in-person event the RevUP Summit, and the parter of this podcast.- ⁠⁠⁠MyPar.org⁠⁠⁠: learn more about the PAR member community- ⁠⁠⁠RevUP Summit⁠⁠⁠: November 4-6, 2025 in Annapolis, MD. The only association event focused on revenue health.

2025P3 Regional Editor of AJPH, Prof. Jihong Liu and Dr. Tianchu Lyu, review highlights of the Apr to Jun 2025 Issues and Supplements. The Editor's Corner includes an interview of Dr. Alfredo Morabia, Outgoing Editor-in-Chief of AJPH, Professor of Epidemiology, Queens College, City University of New York.

Welcome to the Plant-Based Canada Podcast! In today's episode, we're joined by Dr. Joan Sabaté, a renowned physician and nutrition researcher, best known for his work on environmental and sustainable nutrition, and the health benefits of nuts and plant-based diets.Dr. Joan Sabaté MD, PhD is a Professor of Nutrition and Epidemiology. He directs the Environmental Nutrition research program at Loma Linda University School of Public Health and he is also a board-certified physician in Internal Medicine. He was the principal investigator of a nutrition intervention trial that directly linked the consumption of walnuts to significant reductions in serum cholesterol, published in the New England Journal of Medicine in 1993. He is a co-investigator of the Adventist Health Studies, the largest cohort of individuals following a vegetarian diet relating dietary intake with health outcomes. For the past 25 years, he has been the principal investigator of many human nutrition intervention trials investigating the health effects of nuts, avocados, and other plant foods. Dr. Sabaté has authored more than 200 high-impact research articles (with an h-index of 82 and >40,000 citations). Additionally, he was a member of the US 2020 Dietary Guidelines Advisory Committee.Resources:Adventist Health Study 2 Studies: https://pubmed.ncbi.nlm.nih.gov/23836264/; https://pubmed.ncbi.nlm.nih.gov/30487555/Whole-food, plant-based lifestyle intervention trial: https://pubmed.ncbi.nlm.nih.gov/39305340/Review of Plant-Based Milks: https://pubmed.ncbi.nlm.nih.gov/36083996/ 2020 Dietary Guidelines for Americans: https://www.dietaryguidelines.gov/resources/2020-2025-dietary-guidelines-online-materialsNuts & Health: https://pubmed.ncbi.nlm.nih.gov/8357360/https://pubmed.ncbi.nlm.nih.gov/8269904/ https://pubmed.ncbi.nlm.nih.gov/15559025/https://pubmed.ncbi.nlm.nih.gov/10479222/Dr. Joan Sabaté's Socials:Faculty profileInternational Congress of Vegetarian NutritionEnvironmental NutritionLLU Nutrition CenterPlant-Based Canada's Socials:InstagramFacebookWebsiteBonus PromotionCheck out University of Guelph's online Plant-Based Nutrition Certificate. Each 4-week course will guide you through plant-based topics including nutritional benefits, disease prevention, and environmental impacts. Use our exclusive discount code PBC2025 to save 10% on all Plant-Based Nutrition Certificate courses. uoguel.ph/pbn.Thank you for tuning in! Make sure to subscribe to the Plant-Based Canada Podcast so you get notified when new episodes are published. Support the show

In this episode, CancerNetwork® spoke with Joseph S. Wallins, MD, MPH, cardiology fellow at Weill Cornell Medicine, about a review of cardiotoxicities associated with breast cancer treatment he coauthored in the June 2025 issue of ONCOLOGY® titled, “Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment.” Therein, he touched upon data for risk stratification tools for oncologists, as well as the development of cardiovascular testing for individual treatment regimens. Wallins discussed the basis for conducting the systemic review as well as noteworthy cardiotoxicities associated with specific classes of breast cancer therapies. Specifically, he highlighted an increase in cancer remission and survivorship for breast cancer, which has, in turn, created alternative health risks impacting survival outcomes, such as cardiovascular risks. Citing a study showing a nearly 2-fold risk in cardiovascular-related fatalities for breast cancer survivors vs the general population, he suggested that the review was warranted to identify cardiotoxicities, strategies for preventing and managing them, and tools for risk stratification and monitoring. Wallins further outlined considerations for optimizing risk stratification and monitoring strategies in patients at risk of experiencing cardiovascular toxicities as well as treatments that may help with their prevention or mitigation. To that end, he discussed identifying patients who are at a higher risk before initiating treatment and outlined risk assessment tools that serve to do so. Furthermore, he suggested that patients who experience a greater than moderate risk for cardiovascular issues should undergo cardioprotective strategies and have in-depth conversations with providers regarding treatment risks. He concluded by highlighting future steps to enhance cardiovascular outcomes for patients with breast cancer, among additional key takeaways. Of note, Wallins expressed that genetic testing may help elucidate cardiomyopathy-associated genes while calling for a more personalized approach to risk stratification and more sensitive and specific imaging techniques to better identify at-risk patients. Finally, he emphasized a need for upfront risk assessment to identify patients at a higher risk who could benefit from additional testing as well as more pronounced collaboration between oncologists and cardiologists. Reference Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016;27(1):6-13. doi:10.1097/EDE.0000000000000394

Welcome back to Dr. M's Women and Children First podcast where we look at the world of Women and Children's Health through an anthropological lens with the humble understanding that we have a lot to learn. Today, I'm joined by Dr. Joel “Dr. Gator” Warsh, a pediatrician, author, and advocate for a whole-child approach to healthcare. Dr. Warsh earned his medical degree from Thomas Jefferson Medical College and completed his pediatric residency at Children's Hospital of Los Angeles. Along the way, he also obtained a Master's degree in Epidemiology and Biostatistics from Queen's University in Canada, giving him a strong foundation in both clinical care and population health. These educational pursuits make him uniquely suited for today's conversation on vaccines. He is the author of Between a Shot and a Hard Place. In his own words, he says: I've dedicated my career to helping families navigate complicated health topics with clarity. My book addresses vaccine questions in a calm, data-driven, and practical way, offering parents guidance that steers clear of extremes. Parents face unprecedented pressure to make the "right" choices, often without enough balanced information. He has been featured on major platforms sharing his message with more than 400,000 parents through social media. We discuss his passion for empowering families to make informed, individualized decisions, including in areas that have been challenging or even taboo to discuss. Today, we'll dive into his latest work, his perspectives on vaccines and preventative care, and how he envisions a future of pediatrics that is proactive rather than reactive. This is a conversation about rethinking the foundations of child health and it's one you won't want to miss. Enjoy, Dr. M

09/05/25: Dr. Jennifer Nuzzo is Professor of Epidemiology and Director of the Pandemic Center at Brown University School of Public Health. Her work focuses on global health security, public health preparedness and response, and health systems resilience. She joins Joel Heitkamp on "News and Views" to talk about Secretary Robert F. Kennedy's Senate hearing yesterday, and the importance of vaccine transparency. (Joel Heitkamp is a talk show host on the Mighty 790 KFGO in Fargo-Moorhead. His award-winning program, “News & Views,” can be heard weekdays from 8 – 11 a.m. Follow Joel on X/Twitter @JoelKFGO.)See omnystudio.com/listener for privacy information.

About this episode: Animal-to-human transmission of bacteria and viruses have triggered outbreaks of diseases like avian influenza, COVID-19, and Ebola. A public health approach called One Health can help us to better understand these cases—and possibly help prevent future pandemics. In this episode: Professors Emily Gurley and Raina Plowright explain how One Health investigations work, why they're an effective tool for addressing spillover events, and a new One Health Coursera course that you can preview for free: https://www.coursera.org/learn/one-health-investigations-of-outbreaks-and-spillover-events Guest: Emily S. Gurley, PhD, MPH, is a professor in Epidemiology at the Johns Hopkins Bloomberg School of Public Health, where she focuses on infectious disease and outbreak investigation. Raina K. Plowright, PhD, MS, is a veterinarian and the Rudolf J. and Katharine L. Steffen Professor of Veterinary Medicine at Cornell University. Host: Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health. Show links and related content: A Roadmap of Primary Pandemic Prevention Through Spillover Investigation—Emerging Infectious Diseases Healthy Ecosystems, Healthy Humans—Hopkins Bloomberg Public Health Magazine What's the Difference? The Meaning of One Health—Global Health Now Can Spillover—How Viruses Move From Animals to Humans—Be Prevented?—Public Health On Call (November 2021) Transcript Information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Please join my mailing list here

In this foundational episode of Regulated & Relational, Ginger and Julie dive deep into attachment disorders—what they are, how they're diagnosed, and the realities families face when raising children with these challenges.From the history of Reactive Attachment Disorder (RAD) and Disinhibited Social Engagement Disorder (DSED) to the proposed Developmental Trauma Disorder (DTD), Ginger and Julie unpack decades of evolving research, personal experience, and practical tools for caregivers and professionals. They also address the hallmark behaviors—like manipulation, triangulation, lack of empathy—and explore why these behaviors occur, and how to respond in ways that promote healing and connection.This conversation is both honest and hopeful—acknowledging the challenges while sharing effective therapeutic parenting strategies, the importance of pacing and dosing nurture, and the long-term potential for growth and change.The history and evolution of attachment disorder diagnoses in the DSMHow RAD and DSED differ—and why splitting the diagnosis has caused confusionPrevalence rates and why research has been limitedHow attachment disorders can be mistaken for, or co-exist with, autismThe why behind hallmark behaviors:Manipulation and controlTriangulation between adultsLack of cause-and-effect thinkingLow empathyTherapeutic parenting strategies, including:Offering limited, safe choicesMaking implicit care explicitPacing and dosing nurture to build trustReducing chaos and avoiding power strugglesWhy Developmental Trauma Disorder matters—and how it may fill gaps in our understanding of trauma's impact on childrenHopeful outcomes and the critical importance of early intervention and ongoing supportAttachment & Trauma Network: www.attachmenttraumanetwork.orgNational Institute of Health prevalence statistics (2023)Reactive Attachment Disorder - StatPearls - NCBI Bookshelf: https://www.ncbi.nlm.nih.gov/books/NBK537155/ (Published: May 1, 2023)Introduction to children's attachment - NCBI: https://www.ncbi.nlm.nih.gov/books/NBK356196/ https://www.ncbi.nlm.nih.gov/books/NBK537155/#:~:text=Epidemiology,Adolescent%20Well%2DBeing%2C%20No.Research on RAD subtypes: Dr. Charles Zeanah (2004)https://pmc.ncbi.nlm.nih.gov/articles/PMC4342270/ACEs Study: CDC ACEs Resources

A new campaign at UCC aims to make health research more inclusive, to include under-served groups like women, ethnic minorities, LGBTQ+ individuals, older adults, and people with disabilities. Pat hears about it with Frances Shiely, Director of Education and a Professor in patient focused research at the HRB Clinical Research Facility at UCC and a Senior Lecturer in Epidemiology in the School of Public Health.

Dr. John Fleetham chats with Dr. Chris Ryerson and Dr. Yet Khor about their article, "Epidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease."

Our 50th episode of QuidelOrtho Science Bytes features Dr. Jonathan Temte, a leading public health expert, discussing how schools, families, and healthcare providers can stay ahead of respiratory illnesses this school year. As students return to classrooms, familiar viruses like flu, RSV, and COVID-19 often resurge. Dr. Temte explains why symptoms alone can't reliably distinguish between these illnesses and how rapid diagnostics are essential for early detection, accurate treatment, and preventing further spread.    About Our Speaker:  Dr. Temte joined the Department of Family Medicine and Community Health faculty at the University of Wisconsin-Madison in 1993. He is a professor of family medicine and community health and the Associate Dean for Public Health and Community Engagement for the University of Wisconsin School of Medicine and Public Health. Dr. Temte received his BA from Luther College, an MS in Biological Oceanography from Oregon State University, and his PhD in Zoology and Minor in Epidemiology from the University of Wisconsin. He pursued his medical training at the University of Wisconsin Medical School, where he received his MD. Dr. Temte also served as the Director of the Wisconsin Research and Education Network from 2000 to 2005. He chaired the American Academy of Family Physicians Commission on Science in 2008, the AAFP, and he currently chairs the Wisconsin Council on Immunization Practices. He also served as AAFP liaison to the Advisory Committee on Immunization Practices from 2004 to 2008, where he was appointed a voting member from 2008 to 2015 and served as chair from 2012 to 2015. Dr. Temte has also been active on pandemic influenza and bioterrorism working groups for the state of Wisconsin. In addition to his outstanding credentials, Dr. Temte's research interests include respiratory viruses, influenza, COVID-19, schools, and immunization policy.

Send us a textIn this episode of PTs Snacks podcast, we dive into Whiplash Associated Disorder (WAD). Listeners will learn about the nature of whiplash, common causes, and the anatomical structures involved. We discusse how to effectively evaluate patients using various screening tools and questionnaires, and emphasizes the importance of differentiating WAD from other cervical spine traumas. The episode covers best practices for treating WAD through a multimodal approach that includes manual therapy, exercise, patient education, and nerve mobilization. Tips for practicing and screening for red flags are provided, along with insights on how to empower patients through education and active management.00:00 Introduction to PTs Snacks Podcast00:20 Understanding Whiplash Associated Disorder (WAD)01:20 Epidemiology and Causes of Whiplash03:41 Clinical Evaluation and Screening for Whiplash06:26 Treatment Approaches for Whiplash10:08 Patient Education and Reassurance11:12 Conclusion and Additional ResourcesSupport the showWhy PT Snacks Podcast?This podcast is your go-to for bite-sized, practical info designed for busy, overwhelmed Physical Therapists and students who want to build confidence in their foundational knowledge without sacrificing life's other priorities. Stay Connected! Never miss an episode—hit follow now! Got questions? Email me at ptsnackspodcast@gmail.com or leave feedback HERE. Join the email list HERE On Instagram? Find unique content at @dr.kasey.hankins! Need CEUs Fast?Time and resources short? Medbridge has you covered: Get over $100 off a subscription with code PTSNACKSPODCAST: Medbridge Students: Save $75 off a student subscription with code PTSNACKSPODCASTSTUDENT—a full year of unlimited access for less!(These are affiliate links, but I only recommend Medbridge because it's genuinely valuable.) Optimize Your Patient Care with Tindeq: Get 10% off with code PTSNACKS10: [Tindeq] ...

In this special episode on Obstructive Sleep Apnea our host, Dr. Neil Skolnik will discuss treatment of OSA. In Part 1 we discussed and overview of OSA, in Part 2 we discussed making the diagnosis will, and Part 4 will look at cases. This special episode is supported by an independent educational grant from Lilly. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Dr. Sanjay Patel, M.D, Professor of Medicine, Epidemiology, & Clinical and Translational Science, and Director of the Center for Sleep and Cardiovascular Outcomes Research; Medical Director of the Comprehensive Sleep Disorders Program, University of Pittsburgh Medical Center Selected references: Diagnosis and Management of Obstructive Sleep Apnea - A Review. JAMA. 2020;323(14):1389-1400 Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193-1205

Listen as Danny Moore interviews Charlie Larimer on Epidemiology and Predictive Analytics.  Listen as Charlie gives his insight on applying predictive analytics techniques to determine drivers of health outcomes in differing populations and regions.

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

The Trump administration is trying to restrict access to a substance you might find at your local smoke shop. The FDA in late July announced plans to crack down on 7-OH. Commissioner Marty Makary described it as an opioid that can be more potent than morphine and the agency's pushing to get it classified as a Schedule 1 substance -- like ecstasy or heroin. You may not have heard of 7-OH, but you’ve probably heard of kratom. It’s the substance that 7-OH comes from – and it’s controversial in its own right. Some states have banned kratom. The federal government tried to classify it as a Schedule 1 substance in 2016 but opted not to after getting a wave of pushback. This year Washington state regulators withdrew a proposal to designate kratom as a Schedule 1 substance, saying it didn’t meet the criteria. So for now, you can buy kratom products in the state. We wanted to know more about both kratom and 7-OH, so we checked in with a research professor at the University of Washington for insight. Guest: Caleb Banta-Green, research professor at the University of Washington and director of the Center for Community-Engaged Drug Education, Epidemiology and Research. Related stories: FDA recommends concentrated Kratom be scheduled as illicit substance | The Hill What to know about changes to kratom sold in Seattle | Axios Seattle Kratom & 7-OH: What do we know about use, safety, and overdose risk? | Addictions, Drug & Alcohol Institute (University of Washington) What is 7-OH? Opioid-like product may get banned by FDA | USA TODAY Thank you to the supporters of KUOW, you help make this show possible! If you want to help out, go to kuow.org/donate/soundsidenotes. Soundside is a production of KUOW in Seattle, a proud member of the NPR Network.See omnystudio.com/listener for privacy information.

Dr. John Fleetham chats with Dr. Chris Ryerson and Dr. Yet Khor about their article, "Epidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease."

Caroline Lewis, health care reporter for WNYC and Gothamist, and Joe Hong, investigative data reporter for WNYC and Gothamist, talk about the ongoing Legionnaires' outbreak in Central Harlem, why New York is a hot spot for the disease, and why city inspections of cooling towers were at a low point ahead of the outbreak.

Pediatric rheumatologist Dr. Pamela Weiss speaks with Michael and his 12 year old daughter Ava about  navigating the challenge of living with psoriasis and psoriatic arthritis together as a family.   Join moderator Kaleigh Welch as she discusses the challenges of living with psoriasis and juvenile psoriatic arthritis (JPsA) from diagnosis, misconceptions about psoriatic disease, to management and treatment with pediatric rheumatologist, Dr. Pamela Weiss from Children's Hospital of Philadelphia, Division of Rheumatology, along with Michael and Ava, whose psoriatic disease is truly a family affair. The intent of this episode is to raise awareness about the complexities and nuances associated with living with psoriasis and psoriatic arthritis as a child or an adult and not letting the disease stop you from doing what you love to do. This episode is sponsored by Amgen. Mike, Ava, and Dr. Weiss were compensated for their time. Timestamps: ·       (0:00) Intro to Psoriasis Uncovered and guest welcome pediatric rheumatologist Dr. Pamela Weiss, Michael and Ava Sayles who both have been diagnosed with psoriasis and psoriatic        arthritis.   ·       (1:28) What the psoriatic disease diagnosis process could be like for children and adults.   ·       (5:34) Misconceptions associated with psoriasis leading to delayed diagnosis of psoriatic arthritis. ·       (7:36) What people misunderstand about plaque psoriasis and psoriatic arthritis. ·       (11:06) Challenges to finding the right treatment while living life with psoriatic disease. ·       (17:24) What drives treatment choices for psoriatic disease in youth. ·       (19:59) Assessing what's most important in reaching treatment goals. ·       (23:57) What the future holds for management of Juvenile Psoriatic Arthritis (JPsA). ·       (26:10) Living with psoriatic disease is challenging but find what's right for you and don't give up on what you love to do. Key Takeaways: ·       Diagnosis of plaque psoriasis and psoriatic arthritis can be challenging given subtleties that can occur in the presentation of the disease in adults and children. ·       There are a variety of treatments that work either alone or in combination to treat plaque psoriasis and psoriatic arthritis with choice of treatment dependent on what is the primary goal for the individual's physical and emotional health. ·       The future is bright as understanding of the disease increases and treatment options expand and become more targeted to more effectively address skin and joint issues associated with psoriatic disease. Guest Bios:   Pamela Weiss, M.D., MSCE, is a pediatric rheumatologist and the Clinical Research Director of the Division of Rheumatology at Children's Hospital of Philadelphia. Dr. Weiss is also the Distinguished Endowed Chair in the Department of Pediatrics. She has advanced training in clinical epidemiology with a focus on early diagnosis, and targeted treatment of children with spondyloarthritis (SpA). Dr. Weiss is also a Professor of Pediatrics and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania. She is a member of the American Academy of Pediatrics, American College of Rheumatology, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the Spondylitis Association of America, and the SPondyloArthritis Research & Treatment Network (SPARTAN). Michael and Ava Sayles, psoriatic disease is a family affair. Both father and daughter, successfully navigate living with plaque psoriasis and psoriatic arthritis. Michael or Mike was diagnosed in his twenties, and Ava at age 7 and then later on juvenile psoriatic arthritis. She is now 12 years old.  They have experienced issues with diagnosis, and a long journey of finding treatment options that worked for them. Mike found the best solution was establishing a routine or rhythm of treatment around work and school to avoid flare-up's if possible, saying “keeping on top of what you need to do for the psoriasis and the arthritis becomes a big part of your life".  Resources: Our Spot: What is Psoriatic Arthritis  

A quick breakdown of public health jargon in under five minutes. This week's word is at the heart of public health itself: epidemiology.

Watch hol+ by Dr. Taz MD on YouTube: https://www.youtube.com/@DrTazMD/podcastsIf you've ever had questions about childhood vaccine safety, the recommended vaccine schedule, or how to support your child's immune system in a more natural, holistic way, this episode is for you.In this powerful and balanced conversation, Dr. Joel “Gator” Warsh, a board-certified integrative pediatrician, shares his insights on the most common vaccine concerns parents face today.He discusses how he approaches vaccine conversations with parents, how to evaluate the current CDC childhood immunization schedule, and the importance of personalizing healthcare decisions for each child. He also explains how functional medicine and holistic pediatric care can play a role in strengthening children's health, supporting the immune system, and addressing parental concerns in a non-judgmental way.Whether you're looking for answers about vaccine side effects, considering delayed vaccine schedules, or exploring natural alternatives to support pediatric immune health, this episode delivers a research-informed, compassionate, and grounded perspective. We also cover how to reduce shame in health discussions and empower parents with the information they need to make confident decisions.Connect further to Hol+ at https://holplus.co/- Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+About Dr. Joel “Gator” Warsh:Joel Warsh aka DrJoelGator of the popular parenting Instagram is a Board-Certified Pediatrician in Los Angeles, California who specializes in Parenting, Vaccines, Wellness and Integrative Medicine. He is the author of Between a Shot and Hard Place: Tackling Vaccine Questions with Balance, Data, and Clarity. He grew up in Toronto, Canada and completed a Master's Degree in Epidemiology before earning his medical degree from Thomas Jefferson Medical College.He completed his Pediatric Medicine training at Children's Hospital of Los Angeles and then worked in private practice in Beverly Hills before founding his current practice in Studio City.Dr. Gator has published research in peer-reviewed journals on topics including childhood injuries, obesity and physical activity. He has been featured in numerous documentaries, films, summits, podcasts and articles.Stay ConnectedSubscribe to the audio podcast: https://holplus.transistor.fm/subscribeSubscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsFollow Dr. Taz on Instagram: https://www.instagram.com/drtazmd/https://www.instagram.com/liveholplus/Join the conversation on X: https://x.com/@drtazmdTikTok: https://www.tiktok.com/@drtazmdFacebook: https://www.facebook.com/drtazmd/Connect with Dr. Warsh:https://www.instagram.com/drjoelgator/https://linktr.ee/drjoelgatorHost & Production TeamHost: Dr. Taz; Produced by Rainbow Creative (Executive Producer: Matthew Jones; Lead Producer: Lauren Feighan; Editors: Jeremiah Schultz and Patrick Edwards)00:00 Introduction: The Vaccine Debate01:27 Guest Introduction: Dr. Joel “Gator” Warsh03:34 The Importance of Open Dialogue05:55 Understanding Vaccine Polarization12:01 Historical Context: Vaccine Hesitancy13:12 Vaccine Safety and Reporting20:56 The Influence of Big Pharma24:03 Concerns About Vaccine Overload24:51 Dr. Taz's Personal Story27:03 Research Gaps in Vaccine Safety30:39 Autism and Vaccine Hesitancy45:07 Conclusion and Final Thoughts

Focus Issue on Epidemiology, Prevention, and Health Care Policies

Send us a textToday's guest is Dr. Oluwole Babatunde. Dr Babtunde, known to many as “Wole” is a physician-scientist, psychiatrist, epidemiologist, author, and deeply faithful servant-leader whose life journey speaks powerfully to rising through adversity and becoming a beacon for others. Dr. Oluwole Babatundi was born and raised in Nigeria, where his life was forever changed by the loss of both his parents at a young age. While those early experiences of grief and uncertainty could have broken him, instead they ignited a deep sense of purpose and faith that drives Dr. Babatundi today. He was a physician in Nigeria and after coming to the United States, he earned a Ph.D. in Epidemiology. Despite the odds, Dr. Babatundi has published over 60 scientific papers and is the Chief Resident in Psychiatry at Prisma Health in South Carolina. His engaging and inspiring new book is titled ““Adapt and Advance: A Faith-Based Step-by-Step Guide to Turning Trials into Triumphs.” (See link to his book:  https://www.amazon.com/dp/B0F8WDDK6W.) Additional information on Dr. Babatunde can be found at: https://oluwolebabatunde.com.  Support the show

EPISODE 571 - Marc Sapir - I'll Fly Away, 40 Stories about Amazing Disabled EldersMarc Sapir, a retired primary care, geriatric, and public health physician, is an essayist and political activist. He was the first Medical Director of the Center for Elders' Independence for disabled elders for 9 years. He also previously worked for United Farm Workers and was a panel member of the Mad as Hell Doctors for Single Payer Health Care. A graduate of Brandeis University (BA) and Stanford Medical School (MD), he also holds a Master's Degree in Public Health (MPH) epidemiology from the University of California, Berkeley.He is the author of five plays and writes fiction, poetry, and music. He recently published a memoir, Deja Vu with Quixotic Delusions of Grandeur (May, 2024), and his writing has been featured in the San Francisco Chronicle, the San Jose Mercury News, the Berkeley Daily Planet, the Palo Alto Times, the Stanford Daily, Journal of the American Medical Association (JAMA), American Journal of Public Health, American Journal of Epidemiology, and more. He lives in Berkeley, CA.I'll Fly AwayStories about Amazing Disabled Elders by Marc SapirI'll Fly Away invites readers to delve into the intimate narratives of 40 extraordinary elders, revealing their profound stories of resilience and the vibrant spirit that often persists in the twilight years. This collection not only highlights the challenges faced by aging individuals but also champions the beauty and dignity of every life story.“A collection of wonderful real-life stories on aging. Dr. Sapir vividly portrays a complex series of human emotions, struggles, and relationships.”—Thomas Irungu MD, MPH, medical director Sentara Health Plans, VA“Could the lives of 40 disabled oldsters in a geriatric program make interesting reading? ‘Interesting' is an understatement. These stories are fascinating.”—Anthony Somkin MD, medical director RotaCare West Contra Costamarcsapir.netSupport the show___https://livingthenextchapter.com/podcast produced by: https://truemediasolutions.ca/Coffee Refills are always appreciated, refill Dave's cup here, and thanks!https://buymeacoffee.com/truemediaca

Este episódio tem papel duplo: prestar utilidade pública e reforçar a campanha #TodosPeloPirulla - participe você também, contribuindo para a recuperação do amigo, divulgador científico e youtuber Pirulla: vakinha.com.br/vaquinha/pirullaConfira o papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.>> OUÇA (59min 59s)*Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.Edição: Reginaldo Cursino.http://naruhodo.b9.com.br* APOIO: NORDVPNSe você escuta o Naruhodo há algum tempo, sabe que eu trabalho muito remotamente.Isso quer dizer que eu acabo usando muitos wifis públicos. Ou mesmo wifis privados, mas sobre os quais eu não tenho controle. E isso expõe dados meus, tais como senhas, números de cartão de crédito… E até mesmo minha privacidade sobre por onde eu estou navegando.Também quer dizer que, em algumas ocasiões, eu estou num país em que eu não posso acessar o conteúdo que está hospedado em outro país, por algum tipo de restrição técnica.Ou seja: perrengues da vida digital.É pra esses momentos todos que eu uso uma VPN, um serviço que protege sua conexão com a Internet.Mas não qualquer VPN: eu uso a NordVPN. Ela é fácil de instalar. fácil de usar e eu já confio por experiência própria.Por isso te convido a experimentar também a NordVPN com um desconto especial para ouvintes Naruhodo - e, se não ficar satisfeito, pode pedir seu reembolso garantido de 30 dias.É só acessar: https://nordvpn.com/naruhodoNordVPN, a VPN nº 1 de 2025 segundo a TechRadar.*APOIO: INSIDERIlustríssima ouvinte, ilustríssimo ouvinte do Naruhodo,Chegamos mais uma vez no momento INSIDER. E hoje eu quero compartilhar com você uma experiência pessoal.Eu sou relativamente minimalista em meu guarda-roupas: 70% das minhas peças são pretas, 90% delas são lisas.E meu estilo é bem informal: a roupa que eu uso no dia a dia não é tão diferente assim da roupa pra sair.Por isso a INSIDER combinou tanto comigo: ela me proporciona informalidade com sofisticação.Tecido encorpado e cortes modernos, que trazem um caimento perfeito. Peças que eu não preciso passar, que não marcam, que não ficam com mau cheiro - e, principalmente, peças que duram.Estilo despojado, sim, mas sempre com cara de novo. Minha vida fica mais prática e eu fico mais bem vestido.Então, fica aqui meu convite: experimente INSIDER você também e aproveite o desconto de 15% para ouvintes do NARUHODOPara isso, o jeito mais fácil é usar o endereço: creators.insiderstore.com.br/NARUHODOOu clicar no link da descrição deste episódio: o cupom NARUHODO será aplicado automaticamente no carrinho.INSIDER, inteligência em cada escolha.#InsiderStore*REFERÊNCIASVaquinha do Pirulahttps://www.vakinha.com.br/vaquinha/pirullaPathophysiology of Ischemic Strokehttps://link.springer.com/chapter/10.1007/978-981-10-5804-2_4Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trialshttps://pmc.ncbi.nlm.nih.gov/articles/PMC5321490/Cryptogenic stroke: time to determine aetiologyhttps://www.jthjournal.org/article/S1538-7836(22)10551-9/fulltextSummary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular diseasehttps://pmc.ncbi.nlm.nih.gov/articles/PMC3716407/A systematic review and synthesis of global stroke guidelines on behalf of the World Stroke Organizationhttps://journals.sagepub.com/doi/full/10.1177/17474930231156753Dental Management Considerations for the Cardiac Patienthttps://onlinelibrary.wiley.com/doi/abs/10.1111/scd.70048?casa_token=ttBLDqLWGt0AAAAA%3AO1oMHKDSRIFa3VmyQGU7DdblutxTUbu9ryEvRqBoJLUx8AqJhMBvKcnElH5XY2tE88GU3PdTEp8wEx0tClinical diagnosis of stroke subtypes https://www.uptodate.com/contents/clinical-diagnosis-of-stroke-subtypesWorld Stroke Organization: Global Stroke Fact Sheet 2025https://journals.sagepub.com/doi/full/10.1177/17474930241308142Artificial intelligence in stroke rehabilitation: From acute care to long-term recoveryhttps://www.sciencedirect.com/science/article/pii/S0306452225002180?casa_token=NzPfRaWoZOAAAAAA:GEmB6wj1KbQA8dw79yZOaOAnIy416QI0UpvqQlDrz6cCYDgoT7CQ-xwikHLwD8UkNhLlwLhaf40Air pollution and stroke: Short-term exposure's varying effects on stroke subtypeshttps://www.sciencedirect.com/science/article/pii/S0147651325006323Hyperacute stroke care–What's new?https://journals.sagepub.com/doi/full/10.1177/17474930251348387?casa_token=hH0neB-v_E0AAAAA%3A6C706lwrzHGSeV8xAdAUMNudTMYecSZUOVTxCCKUpUfGN0pv7mezUIUcprlNfTQ8JirCLmi7CKlPDgAdvances in Epidemiology, Outcomes, and Population Science in 2024https://www.ahajournals.org/doi/abs/10.1161/STROKEAHA.125.049886Chain mediating effect of frailty and depression between nutrition and quality of life in elderly stroke patients https://www.tandfonline.com/doi/abs/10.1080/13548506.2025.2502843Telemedicine and Post-Acute Care Demands: Evidence from Stroke Patientshttps://aisel.aisnet.org/pacis2025/ishealthcare/ishealthcare/17/The global prevalence of oropharyngeal dysphagia in different populations: a systematic review and meta-analysishttps://link.springer.com/article/10.1186/s12967-022-03380-0Stroke–heart syndrome: clinical presentation and underlying mechanismshttps://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30336-3/abstractBrain–heart interaction after acute ischemic strokehttps://link.springer.com/article/10.1186/s13054-020-02885-8Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Strokehttps://www.ahajournals.org/doi/full/10.1161/STROKEAHA.121.037316Impact of OSA on cardiovascular events after coronary artery bypass surgeryhttps://pubmed.ncbi.nlm.nih.gov/25612013/Sleep apnea prevalence and severity after coronary revascularization versus no intervention: a systematic review & meta-analysishttps://link.springer.com/article/10.1007/s11325-024-03164-4Obstructive Sleep Apnea and Outcomes in Cardiac Surgery: A Systematic Review with Meta-Analytic Synthesis (PROSPERO CRD420251049574)https://www.mdpi.com/2227-9059/13/7/1579Guidelines for the Prevention of Stroke in Women A Statement for Healthcare Professionals From the American Heart Association/American Stroke Associationhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10152977/Clipe da Música Prevenção Contra o AVC 2017https://www.youtube.com/watch?v=F1GjcMJTdeQNaruhodo #236 - Por que temos dor de cabeça?https://www.youtube.com/watch?v=q8FtXVlSz1INaruhodo #264 - Por que é importante conhecer nosso colesterol?https://www.youtube.com/watch?v=5D3ezsGM_5sNaruhodo #256 - Por que roncamos?https://www.youtube.com/watch?v=SfJH_F2GsI4Naruhodo #162 - Por que acontece o nocaute?https://www.youtube.com/watch?v=_UmiDEjZmfcNaruhodo #163 - O que a anestesia desliga no nosso corpo?https://www.youtube.com/watch?v=6IoMagNybTINaruhodo #217 - Por que algumas pessoas tremem?https://www.youtube.com/watch?v=K7KLyBBnK_Q*APOIE O NARUHODO!O Altay e eu temos duas mensagens pra você.A primeira é: muito, muito obrigado pela sua audiência. Sem ela, o Naruhodo sequer teria sentido de existir. Você nos ajuda demais não só quando ouve, mas também quando espalha episódios para familiares, amigos - e, por que não?, inimigos.A segunda mensagem é: existe uma outra forma de apoiar o Naruhodo, a ciência e o pensamento científico - apoiando financeiramente o nosso projeto de podcast semanal independente, que só descansa no recesso do fim de ano.Manter o Naruhodo tem custos e despesas: servidores, domínio, pesquisa, produção, edição, atendimento, tempo... Enfim, muitas coisas para cobrir - e, algumas delas, em dólar.A gente sabe que nem todo mundo pode apoiar financeiramente. E tá tudo bem. Tente mandar um episódio para alguém que você conhece e acha que vai gostar.A gente sabe que alguns podem, mas não mensalmente. E tá tudo bem também. Você pode apoiar quando puder e cancelar quando quiser. O apoio mínimo é de 15 reais e pode ser feito pela plataforma ORELO ou pela plataforma APOIA-SE. Para quem está fora do Brasil, temos até a plataforma PATREON.É isso, gente. Estamos enfrentando um momento importante e você pode ajudar a combater o negacionismo e manter a chama da ciência acesa. Então, fica aqui o nosso convite: apóie o Naruhodo como puder.bit.ly/naruhodo-no-orelo

In this JACC Deep Dive, Editor-in-Chief Harlan M. Krumholz, MD, SM, discusses a large real-world study by Min et al. examining heart failure with improved ejection fraction (HFimpEF) in over 24,000 patients. The study found that while EF improvement is common (30%), true remission is rare and relapse occurs in about 25% of cases—highlighting the need for continued guideline-directed medical therapy (GDMT) even after apparent recovery. Listen to the podcast, find out what reviewers and editors liked about the paper, and get more insight into our dedicated focus issue on heart failure.

Have you ever wondered what happens when a toddler gets into something they definitely shouldn't? Today, Dr. Monica Gray, Dr. Pradip Kamat, and Dr. Rahul Damania discuss the case of an 18-month-old boy who accidentally ingested concentrated bleach, presenting with stridor, drooling, and vomiting. They review the clinical approach to caustic ingestions in children, including airway management, diagnostic workup, and the roles of endoscopy, steroids, and multidisciplinary care. The episode also highlights potential complications such as esophageal strictures and cancer, emphasizes prevention strategies, and provides key takeaways for intensivists managing similar pediatric emergencies. If you're an intensivist or just want to know what to do in a pediatric emergency, don't miss these essential takeaways for managing one of the scariest situations in the ER.Show Highlights:Case study of an 18-month-old boy who ingested concentrated bleachClinical presentation including symptoms like stridor, drooling, and vomitingManagement strategies for caustic ingestions in childrenImportance of airway management and monitoring in cases of caustic ingestionDiagnostic workup including imaging and endoscopyDifferential diagnosis considerations for similar presentations (e.g., button batteries, laundry detergent pods)Mechanism of injury caused by alkaline substances like bleachLong-term complications associated with caustic ingestions, such as esophageal strictures and cancerMultidisciplinary approach to treatment involving various medical specialtiesPrevention strategies to reduce the incidence of accidental caustic ingestions in childrenReferences:American Academy of Pediatrics – Pediatric Care Online: Esophageal Caustic Injury (AAP clinical guidance on caustic ingestions).Fuhrman & Zimmerman's Pediatric Critical Care textbook – Chapters on toxicology and gastrointestinal emergencies (covering caustic injury management and critical care approach).Hoffman RS, et al. “Ingestion of Caustic Substances.” New England Journal of Medicine. 2020; 382(18):1739-1748. A comprehensive review of caustic ingestion injuries and management.Arnold M, Numanoglu A. “Caustic ingestion in children – a review.” Semin Pediatr Surg. 2017;26(2):95-104. Review of epidemiology, pathophysiology, and treatment of caustic injuries in kids.Johnson CM, Brigger MT. “The public health impact of pediatric caustic ingestion injuries.” Arch Otolaryngol Head Neck Surg. 2012;138(12):1111-1115. (Epidemiology study showing declining incidence).Pediatric Critical Care Medicine (PCCM) Journal – various case reports and series on caustic ingestion (for case-based insights), and annual National Poison Data System reports (for statistics on pediatric poisonings).Tringali A, et al. ESGE/ESPGHAN Pediatric GI Endoscopy Guidelines (Endoscopy, 2017) – Includes recommendations for endoscopy timing and steroid use in caustic ingestions.Usta M, et al. “High doses of methylprednisolone in the management of caustic esophageal burns.” Pediatrics. 2014;133(6):E1518-24. (Key study demonstrating steroids benefit in grade 2b injuries).Royal Children's Hospital Melbourne – Clinical Practice Guidelines: Caustic Ingestions (2019) – Practical hospital guidelines emphasizing early intubation for airway threat, endoscopy within 24h, IV PPI, and supportive care.

LISTENER DISCRETION IS ADVISED. More thoughts on OB Learning 12-leads Paralytic choices ALS for AMS Cash RE, Kaimal AJ, Samuels-Kalow ME, Boggs KM, Swanton MF, Camargo CA Jr. Epidemiology of Emergency Medical Services-Attended out-of-Hospital Deliveries and Complications in the United States. Prehosp Emerg Care. 2024;28(7):890-897. Dexter F, Epstein RH, Wachtel RE, Rosenberg H. Estimate of the relative risk of succinylcholine for triggering malignant hyperthermia. Anesth Analg. 2013 Jan;116(1):118-22. Nunnally ME, O'Connor MF, Kordylewski H, Westlake B, Dutton RP. The incidence and risk factors for perioperative cardiac arrest observed in the national anesthesia clinical outcomes registry. Anesth Analg. 2015 Feb;120(2):364-70.